SCHEMBL5656421

SCHEMBL5656421

Fc1ccc(ON2CCCCC2)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.40
SLC6A2 P23975 2/20 0.37
SLC6A3 Q01959 2/20 0.37
TSHR P16473 2/20 0.37
SLC6A4 P31645 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
GAA P10253 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HTT P42858 1/20 0.37
HPGD P15428 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3073484 0.84 KDM4E (0.47) NPC1RAB9AKDM4ESMN1; SMN2TSHR
Trifluoroacetic Acid SCHEMBL23854114 0.82 NPC1 (0.41) NPC1RAB9AKDM4ESMN1; SMN2TSHR
SCHEMBL3964727 0.79 NPC1 (0.41) NPC1RAB9AMAPTALDH1A1MEN1
SCHEMBL16825239 0.79 KDM4E (0.43) NPC1RAB9AKDM4ESMN1; SMN2TSHR
SCHEMBL16825171 0.79 NPSR1 (0.44) NPC1RAB9ASMN1; SMN2TSHRMAPT
SCHEMBL6242418 0.78 TSHR (0.53) NPC1RAB9AKDM4ESMN1; SMN2TSHR
SCHEMBL27792560 0.76 KDM4E (0.40) NPC1RAB9AKDM4ESMN1; SMN2LMNA
SCHEMBL3174770 0.76 TSHR (0.50) NPC1RAB9ASMN1; SMN2SLC6A2SLC6A3
SCHEMBL3825653 0.71 ALDH1A1 (0.46) KDM4ESMN1; SMN2TSHRLMNAGAA
SCHEMBL28224399 0.71 ALDH1A1 (0.62) KDM4ESMN1; SMN2LMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3074377-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF Genentech, Inc. (US) 2016-10-05 EP disclosed
WO-2015078374-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-06-04 WO disclosed
US-7304077-B2 Chemical compounds ASTRAZENECA AB (SE) 2007-12-04 US disclosed
US-20040102432-A1 Chemical compounds ASTRAZENECA AB (SE) 2004-05-27 US disclosed
EP-1322611-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-07-02 EP disclosed
WO-2002020484-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102432-A1 Chemical compounds CCL11, HRH1, HRH4 NPC1 842/4885RAB9A 1454/4885KDM4E 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.